Glaukos price target raised to $125 from $120 at Truist

Truist raised the firm’s price target on Glaukos to $125 from $120 and keeps a Buy rating on the shares. The company’s Q1 results were “solid”, with the beat and raise being highlighted by implied iDose upside, the analyst tells investors in a research note. As long as iDose momentum is building, investors can stay excited and the “stock can work”, Truist added.